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ABSTRACT 
The spatial distribution of radiopharmaceuticals that emit short-range high linear-energy-
transfer electrons greatly affects the absorbed dose and their biological effectiveness. The 
purpose of this study was to investigate the effect of heterogeneous radionuclide distribution 
on tumor control probability (TCP) in a micrometastases model. 
Methods: Cancer cell lines; MDA-MB-468, SQ20B and 231-H2N were grown as spheroids 
to represent micrometastases. The intracellular distribution of a representative radiopeptide 
(111In-labelled epidermal growth factor, EGF) and radioimmunotherapeutic (111In-labelled 
Trastuzumab) was determined in cell internalization experiments. The intratumoral 
distribution was evaluated by microautoradiography of spheroids. γH2AX staining was 
performed on spheroid sections to correlate DNA damage with radionuclide distribution. 
Experimental surviving fractions (SFexp) were obtained using clonogenic assays. A random 
closed-packed algorithm, which models the random packing behavior of cells and reflects 
variation in the radii of cells and nuclei, was used to simulate 3-D spheroids. Calculated 
survival fractions (SFcal) were generated using an iterative modelling method based on Monte 
Carlo determined absorbed dose with the PENELOPE code and were compared to SFexp. 
Radiobiological parameters deduced from experimental results and MC simulations were 
used to predict the TCP for a 3-D spheroid model.  
Results: Calculated SFs were in good agreement with experimental data, particularly when 
an increased value for relative biological effectiveness (RBE) was applied to self-dose 
deposited by sources located in the nucleus and when radiobiological parameters were 
adjusted to account for dose protraction. Only in MDA-MB-468 spheroids treated with 111In-
EGF was a TCP>0.5 achieved, indicating that for this cell type the radiopeptide would be 
curative when targeting micrometastases. This is attributed to the relative radiosensitivity of 
MDA-MB-468 cells, high nuclear uptake of the radiopeptide and uniform distribution of 
radioactivity throughout the spheroid. 
Conclusions: It is imperative to include biological endpoints when evaluating the distribution 
of radionuclides in models emulating micrometastatic disease. The spatial distribution of 
radioactivity is a clear determinant of biological effect and TCP as demonstrated in this 
study. 
Key words: Auger-electrons, MC modelling, 3-D spheroids, dosimetry, TCP. 
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INTRODUCTION 
The predicted radiobiological effect (RBE) of targeted radionuclide therapy (TRT) is often 
extrapolated from that of external beam radiotherapy (EBRT). It is assumed that the 
biological response to TRT will be similar to that of EBRT when an equivalent radiation 
absorbed dose is delivered to the tumor as a whole. However, the biological response to TRT, 
varies substantially with differences in expression of the molecular target, which in turn 
results in spatial non-uniformity of radioactivity and energy deposition and thus absorbed 
dose (Gy), at the whole tumor, cellular and subcellular levels. It is postulated that Auger 
electron (AE)-emitting radionuclides that bind or intercalate into DNA are ideal for TRT of 
single cells, limited volume disseminated cancer and micrometastases (1,2). This hypothesis 
is based on the high linear-energy transfer (LET) (4-26 keV/μm) of low-energy AE that 
deposit energy within a few cubic nanometers of the decay site (1,3). The localized 
absorption of electrons results in complex irreparable DNA damage (4). This feature endows 
AE-emitting TRT agents with an enhanced RBE when compared to α- or β-emitting 
radionuclides. 
To advance our understanding of the radiobiology of AE-emitting therapeutics and to test the 
hypothesis that they are ideally suited to the treatment of micrometastases, appropriate 
biological models that reflect the in vivo 3-D architecture and physiology of tumors are 
required. Also, a dosimetric approach, which takes account of both the intratumoral and 
intracellular distribution of radioactivity, is necessary (5). Multicellular tumor spheroids are 
excellent models of micrometastases as they reflect the cellular heterogeneity, physiological 
gradients (6,7) and resistance to therapy of small tumors (8). By combining experimental data 
detailing the dose distribution in individual cells and in whole spheroids with Monte Carlo 
(MC) modelling, radiobiological quantities such as tumor control probability (TCP), that 
relate the fate of individual cells to a macroscopic outcome, can be calculated (9,10). Several 
MC studies focusing on the charge transport of AE in volumes representing small cell 
clusters have explored whether the dose deposited would be sufficient to illicit a tumoricidal 
effect (11,12). However, to date only a few studies have attempted to validate MC 
simulations that predict the efficacy of AE-emitters with experimental observations (13-15).  
In this study the efficacy of radiolabeled peptide- and antibody-based constructs was 
evaluated in spheroids generated from three cancer cell lines. 111In-DTPA-human epidermal 
growth factor (hereafter “111In-EGF”), which causes selective radiotoxicity in EGF receptor 
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(EGFR)-overexpressing cells, was used as a representative radiopeptide and 111In-DTPA-
Trastuzumab (hereafter “111In-Tz”), which binds the human EGFR-2 (HER2/neu) receptor, 
was used as a representative radioimmunotherapeutic (16,17). Data derived from cell 
internalization and spheroid microautoradiography (MAR) experiments were used to build 
realistic in silico MC models. These models were used to predict TCP and validated against 
experimentally derived values. 
MATERIALS AND METHODS 
3-D Culture of Spheroids 
Human breast cancer cell lines MDA-MB-468 (1.3x106 EGFR/cell; HER2 low) and 231-H2N 
(0.2x106 EGFR, 6.1x105 HER2/cell) and a human head and neck squamous carcinoma cell 
line, SQ20B (1.0x106 EGFR/cell, HER2 low) (16,18), were grown in Dulbecco’s Modified 
Eagle’s Medium (Sigma-Aldrich, Dorset, UK) supplemented with 10% fetal bovine serum 
(FBS; Invitrogen, Paisley, UK), 100 units/mL penicillin and 100 µg/mL streptomycin 
(Sigma-Aldrich) at 37°C in 5% CO2. MDA-MB-468 and SQ20B cells were obtained from 
American Type Culture Collection, 231-H2N cells from Robert Kerbel, Sunnybrook Health 
Sciences Centre, Toronto. Spheroids were generated using the InSphero hanging droplet 
method. MDA-MB-468 (10,000 cells/well), 231-H2N (40,000 cells/well in InSphero 3-D 
culture medium) and SQ20B (20,000 cells/well) were seeded into GravityPLUS™ plates 
(InSphero AG, Zurich, Switzerland). Spheroids were transferred to GravityTRAP™ plates on 
Day 4. 
Microautoradiography and Immunofluorescence 
Synthesis of 111In-EGF and 111In-Tz was performed as previously described (16,19). 
Spheroids were exposed to 111In-EGF (8 MBq/µg; 40 nM) or 111In-Tz (6 MBq/µg; 10 nM) for 
1 or 24 h and then fixed for 30 min (4% paraformaldehyde), washed in PBS and placed in a 
cryomould (Agar scientific, UK) containing Tissue Tek O.C.T. (Electron Microscopy 
Sciences, PA, USA). Samples were flash frozen and stored at -80ºC. Samples were sectioned 
into 8 µm-thick sections, thaw mounted on Superfrost® Plus microscopy slides (VWR Int., 
Leuven, Belgium) and dried at room temperature for at least 30 min before coating with 
Kodak NTB emulsion (VWR Int., Leicestershire, UK). Slides were stored in a light tight box 
for 24 h at 2-8°C until development (Kodak D-19, Sigma-Aldrich) and fixation (Kodak 
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polymer RT, 1:4, Sigma-Aldrich). γH2AX staining was performed as previously described 
(18) on sequential spheroid sections to evaluate DNA damage. 
Sub-Cellular Distribution of Radioactivity 
Cells (1x106 cells/mL), were exposed to 111In-EGF (8 MBq/µg; 40 nM) or 111In-Tz (6 
MBq/µg; 10 nM) for 1 or 24 h. Unbound, membrane-bound, cytoplasmic and nuclear 
fractions were collected as previously described (16) and using a Subcellular Protein 
Fractionation Kit (Thermo Fischer). Purity of fractions was confirmed by western blot 
analysis of known membrane, cytoplasmic and nuclear proteins: beta integrin, alpha tubulin 
and H2AX. The amount of radioactivity in each fraction was measured by γ-counter 
(PerkinElmer Wizard 1470, Waltham, MA, USA).  
Cell Size Measurement 
Cells were cytospun onto slides and fixed (4% PFA, Sigma-Aldrich) for 15 min at 37˚C. 
After washing with PBS, cells were covered in a membrane specific stain, wheat germ 
agglutinin (5.0 µg/mL) conjugate (WGA-Alexa Flour-488, Thermo Fisher Scientific, 
Basingstoke, UK) for 10 min followed by DAPI staining of cell nuclei. Cells were washed in 
PBS and mounted with Vectashield mounting medium (Vector Laboratories, Peterborough, 
UK) before microscopy (TCS SP2 microscope, Leica Microsystems, UK). Cell and nuclei 
radii were taken as the average of n=30 stained cells. 
MC Simulation  
To represent 3-D spheroids in silico, an event-driven molecular dynamics algorithm (20) for a 
system of monodisperse spherical random close-packed (RCP) cells was used (21,22). Event-
by-event simulation was performed using the MC code PENELOPE (23) and the complete 
electron spectrum of 111In based on the unabridged nuclear decay data (BrIccEmis) (24). The 
photon absorbed fraction was negligible and therefore omitted (5). A total of 1x108 primary 
particles were simulated. Simulations were performed in liquid water and the spatial 
distribution of radioactivity within a spheroid was based on MAR results. Two scenarios 
were considered (reflecting MAR staining): uniform distribution of radioactivity throughout 
the spheroid or peripheral accumulation. The radioactivity in each cell of the MC model was 
informed by experimental sub-cellular internalization data. Absorbed fractions (S-values), 
derived from dose-point kernels of an 111In point source in liquid water using the terminology 
described in (1), were calculated for contributions from a source cell to its nucleus (N←Cs), 
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the cytoplasm to its nucleus (N←Cy) and the nucleus to itself (N←N). The cross-dose was 
derived from the difference between the self-dose and simulated total dose (25). S-values 
were calculated for single cells, monolayers and cell clusters, the latter two using the RCP 
algorithm. 
Survival Fraction and Tumor Control Probability Calculation 
Clonogenic survival assays were performed on monolayers of MDA-MB-468, SQ20B and 
231-H2N cells treated with 111In-EGF (8 MBq) or 111In-Tz (6 MBq) as previously described 
(16). The radiosensitivity parameters, α and β, were determined for each cell line after 137Cs 
irradiation (1 Gy/min) by fitting the average SF from three independent experiments using 
least-squares regression by the linear quadratic model. α and β values were 0.46 and 0.003 for 
MDA-MB-468, 0.20 and 0.001 for SQ20B and 0.12 and 0.06 for 231-H2N cells. 
The survival probability of an individual cell,  
 
, follows the linear-quadratic model (LQM) 
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with Di the absorbed dose (Gy) of an individual cell, α and β determined from 137Cs 
irradiation and G the Lea-Catcheside factor which accounts for radiation damage repair 
(Supplemental Material). Dose was calculated according to the MIRD formulation (26), 
where Di is taken as the product of accumulated activity   in each cell compartment with its 
associated S-value, where τ is the target (nucleus) and σ the source (i.e. N, Cy or Cs);   
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Thus the TCP of a 3-D spheroid, which is defined as the probability of killing all cells within 
the spheroid, is given as 
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Statistical Analysis 
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Statistical analyses were performed using GraphPad Prism® (version 5, GraphPad Software, 
Inc, USA). Internalization and clonogenic SF data were analysed using two-way ANOVA 
with Sidak's multiple comparisons test and Tukey’s multiple comparison test respectively. 
Statistical significance is reported as p<0.05.  
RESULTS 
3-D Spheroid Model  
A 3-D rendering of an in silico MDA-MB-468 spheroid, a cross section through a smaller 
cluster (to demonstrate variation in cell and nucleus size), and the relationship between radii 
of cells and nuclei are shown in Fig. 1. MDA-MB-468 spheroids comprised of loosely 
associated cells compared to 231-H2N and SQ20B spheroids (Fig. 2A-C). SQ20B cells 
formed spheroids with a rim of tightly packed cells with less densely packed cells toward the 
center. Cell and nucleus radii (Rc, Rn) in µm used for MC simulations were; MDA-MB-468: 
Rc=9.45±1.71, Rn=6.65±1.30; SQ20B: Rc=10.61±1.24, Rn=8.10±1.39 and 231-H2N: 
Rc=11.21±2.59, Rn=7.09±1.44 (Fig. 2D-F). The radius of each cell and corresponding 
nucleus were sampled from an empirical distribution of the cell line radii, taking into 
consideration the correlation between the two (Supplemental Fig. 1).  
Radioactivity Uptake and DNA Damage in Spheroids 
111In-EGF: At 1 h, 111In-EGF accumulated at the periphery of EGFR-positive MDA-MB-468 
and SQ20B spheroids (Figs. 3A and 4A). Control untreated spheroids are shown for 
comparison (inset images, Figs. 3A and 4A). By 24 h, 111In-EGF had accumulated throughout 
MDA-MB-468 spheroids (Fig. 3B), while peripheral accumulation persisted in SQ20B 
spheroids (Fig. 4B). γH2AX induction reflected radioactivity distribution, and at 24 h was 
observed throughout MDA-MB-468 spheroids (Fig. 3C), but was restricted to the periphery 
in SQ20B spheroids (Fig. 4C). The amount of 111In-EGF that had accumulated in whole cells 
and in membrane, cytoplasmic and nuclear fractions by 1 and 24 h is shown for MDA-MB-
468 (Figs. 3D) and SQ20B cells (Fig. 4 D). In MDA-MB-468 cells, membrane and 
cytoplasmic fractions increased significantly with time (p<0.0001). Nuclear accumulation 
remained virtually constant in SQ20B cells, while the cytoplasmic fraction increased 
significantly with time (p<0.0001). EGFR-low 231-H2N cells showed minimal 111In-EGF 
internalization, while spheroids showed little MAR (Supplemental Fig. 2) or γH2AX staining 
(data not shown). 
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111In-Tz: There was little MAR staining and accumulation of 111In-Tz in the HER2-low cell 
lines MDA-MB-468 or SQ20B (Supplemental Fig. 3). Peripheral accumulation of 
radioactivity was seen after 1 h incubation in HER2-high 231-H2N spheroids (Fig. 5A), with 
even distribution throughout the spheroid by 24 h (Fig. 5B). It is possible that the relatively 
sparse γH2AX staining in HER2-high 231-H2N (Fig. 5C) compared to MDA-MB-468 
spheroids, despite uniform and marked accumulation of radioactivity throughout the whole 
spheroid, could be explained by the relatively low nuclear accumulation of 111In in 231-H2N 
versus MDA-MB-468 cells.  
Clonogenic Survival 
Following exposure to 111In-EGF the surviving fraction (SF) of MDA-MB-468 cells 
decreased to 71±10% after 1 h (p<0.001), and to 1±1% (p<0.0001) after 24 h (Fig. 6A). For 
SQ20B cells, SF was 9±3 % at 24 h (p<0.0001). 231-H2N cells express the smallest number 
of EGFR and internalized the least activity; this is reflected in the SF of 99±5 % at 24 h.  
111In-Tz did not have a statistically significant effect on SF in the HER2-low cell lines MDA-
MB-468 and SQ20B (Fig. 6B). However, cell survival in the HER2-positive cell line, 231-
H2N, was significantly different at 24 h compared to 1 h (p<0.0001), with SF decreasing to 
46±9 % at 24 h. 
MC simulation 
S-values: MC calculated S-values for single cells, monolayers and cell clusters are 
summarized in Table 1. Single-cell S-values are in good agreement with MIRDCell values 
with differences ≤ 2%. RCP S-values for monolayers and clusters take cross-fire from 
neighboring cells into account. As a result of the variation in cell size and RCP, S-values are 
given as an average value and standard deviation. The greatest effect of crossfire was noted in 
cytoplasmic and cell-surface contributions, where S(N←Cy) increased by at least a factor of 
two in monolayer and almost a factor of 3 in spheroids across all cell lines, when compared 
with single cell S-values. In the case of 231-H2N, S(N←Cs) contribution from RCP increased 
almost 5-fold compared to single cells. A graphical illustration of the contribution of cross 
dose to the total dose for cell clusters as a function of a radial distance from spheroid center, 
is shown in Supplemental Fig. 4 and the total contributions are summarized in Supplemental 
Table 1.  
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SF and TCP evaluation: Cell compartment-specific uptake of the peptide and antibody 
constructs was evaluated to inform MC calculated SF
 
(SFcal). Trapezoidal integration of the 
total activity at 1 and 24 h in the different cellular compartments provided the data necessary 
to calculate accumulated activity ( ) (Table 2). Absorbed dose was then calculated (equation 
2) and SFcal determined using S-values for 3-D spheroids (Table 2). Assumptions made were 
that the activity internalized in a single cell is representative of that in cells within a spheroid 
and that the experimental SF (SFexp) determined for monolayers is applicable to spheroids.   
SFexp (Fig. 6) and SFcal were compared with MIRDcell calculated SF (Table 2) (12). MC 
model 1, MC(1), and MIRDcell are both based on α- and β-values derived from 137Cs 
irradiation, the only difference being the packing algorithms used. MIRDcell assumes 
uniform cell and nucleus sizes in a close-packed cubic lattice. Across all cell lines the 1 h SF 
data of MIRDcell and MC(1) are in good agreement (<5% difference). However, MIRDcell 
SF are consistently lower (by up to 40%) at 24 h compared to MC(1). This is partly due to the 
higher cross-dose contribution from cubic lattice packing compared to RCP and the variation 
in cell/nucleus size in the RCP cluster. If a threshold dose is required to kill a cell of a certain 
size, smaller cells will be killed but not bigger cells – with uniform cell sizes, all cells 
reaching that threshold dose will die. Neither model however, predicts SFexp adequately. The 
second iteration, MC(2) assumes a greater RBE when AE-emitters accumulate in the nucleus 
of a cell. MC(2) and SFexp are in good agreement across all cell lines apart from 24 h SF data 
for the radioresistant cell line 231-H2N. This discrepancy can be attributed to the 
combination of the suppressed Lea-Catcheside factor, G (Supplemental Material Eq. 1) 
following 24 h of low-dose-rate exposure and radioresistance of the 231-H2N cell line (low 
α/β ratio and high β). The next iteration, MC(3) is similar to MC(2) but also accounts for the 
suppression of G factor following exposure to 111In for 1 and 24 h. MC(3) only differs 
significantly from MC(2) for 231-H2N cells and the SFs derived using this model are in good 
agreement with the SFexp.  
When radioactivity is restricted to the periphery of the spheroids, the calculated TCP 
becomes zero. If physical decay alone is considered, and no further internalization of 111In-
conjugated constructs is allowed after 24 h, only MDA-MB-468 spheroids exposed to 111In-
EGF, achieve a TCP of 50% for all three MC models (after 5.3, 1.9 and 2 days for MC(1), 
MC(2) and MC(3), respectively). This is evident from Fig. 7 where unlabeled cells receive 
negligible doses due to the weak cross-fire effect associated with 111In.  
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DISCUSSION 
Here, the efficacy of a peptide and antibody delivery strategy for AE-targeted radiotherapy 
was evaluated in spheroid models of three different cell lines, namely; MDA-MB-468, 
SQ20B and 231-H2N. Spheroid morphology was then used to generate 3-D geometry models 
for MC simulation to predict TCP using data from activity distribution, internalization and 
survival assays to build realistic in silico models. 
It was immediately evident that spheroid morphology differed between cell lines. MDA-MB-
468 cells did not form compact round spheroids as was the case with the other breast cancer 
cell line, 231-H2N, (Fig. 2) but rather loosely aggregated cells, a characteristic previously 
observed by Ivascu et al (6). This loose aggregation of cells facilitated the penetration of the 
111In-labelled peptide as seen on MAR images, which showed a large accumulation of silver 
grains on the rim of MDA-MB-468 spheroids after a 1 h incubation with 111In-EGF which 
spread over the whole spheroid section after incubation for 24 h (Fig. 3A and B). In contrast, 
SQ20B speheroids consisted of tightly packed cells at the periphery compared with the core. 
It is possible that the dense outermost cell layers established a diffusion barrier, which 
prohibited the penetration of the radiopeptide. MAR results confirmed that the accumulation 
of silver grains were mostly restricted to the rim of the spheroid at 1 and 24 h (Fig. 4A and 
B). The EGFR-low cell line, 231-H2N, showed little positive MAR staining at either time 
point (Supplemental Fig. 3). The situation was reversed when evaluating the spatial 
distribution of the 111In-labelled antibody, 111In-Tz. HER2-low cell lines, MDA-MB-468 and 
SQ20B showed barely any MAR staining at 1 and 24 h (Supplemental Fig. 4) whereas 111In-
Tz treated 231-H2N spheroids showed a peripheral staining pattern at 1 h which spread 
throughout the spheroid at 24 h (Fig. 5 A and B).  
MAR staining, although informative, does not take into account the non-uniform radionuclide 
distribution within individual cells which could significantly alter the energy deposition in the 
cell (or cell nucleus), especially in the context of short-range electron emission (13). Hence, 
MAR staining was used to provide a global representation of activity distribution, while 
internalization assays provided activity distribution at a sub-cellular level. To confirm that 
activity distribution correlated with DNA damage, γH2AX staining was performed. γH2AX 
staining patterns for 111In-EGF-treated MDA-MB-468 and SQ20B spheroids after 24 h 
correlated well with MAR, showing γH2AX induction throughout the MDA-MB-468 
spheroid and peripheral induction only in the SQ20B spheroid. There was less γH2AX 
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induction in SQ20B cells compared with MDA-MB-468 cells as the latter accumulated 
almost twice the nuclear activity. With 111In-Tz-treated 231-H2N spheroids, γH2AX foci 
(Fig. 5C) were sparsely distributed compared to 111In-EGF-treated MDA-MB-468 spheroids 
(Fig. 3C), which was initially surprising given the uniform MAR staining in both spheroid 
models. On closer inspection it is clear from internalization data that most of the activity was 
bound to the surface of 231-H2N cells, which would explain the less abundant γ-H2AX 
staining.  
To relate accumulated activity with cell survival after 1 and 24 h treatment with the 111In-
labelled peptide and antibody constructs, clonogenic assays were performed using cells 
grown in monolayers (Fig. 6). An assumption made here is that SFs measured in monolayers 
can be extrapolated to 3-D spheroids given the same subcellular distribution of activity. It 
would of course be more informative to use treated spheroids for clonogenic assays, however 
in our hands disaggregation of spheroids after radionuclide treatment lead to significant cell 
loss with the result that colony counting experiments were not reproducible. Rae and Mairs 
(27) recently discussed the utility of using a multicellular spheroid growth assay as an 
alternative measure of clonogenicity. However, since our endpoint was to determine TCP of 
the different AE-treatment strategies, estimation of clonogenic SF was necessary. These data 
were then used with MC calculated S-values to estimate absorbed dose. In addition, these 
data were compared with MIRDCell data. The MIRDcell software provides estimates of S-
values in single cells, cell-monolayers and cells cluster in a close-packed geometry, and 
predicts the SF of targeted and non-targeted cell populations in the latter (12). Although 
close-packed hexagonal or cubic lattices as used by MIRDcell are mathematically simpler 
models than RCP algorithms, they do not reflect the disorganized cellular architecture of 
tumors, nor do they account for the non-uniform distribution of cell/nucleus sizes (28,29). S-
values are greatly affected by cell volume, thus S-values (and hence dose) may be 
significantly under- or over-estimated when variation in cell volume is ignored. Furthermore, 
activity is often assumed to be homogeneously distributed to simplify simulation. Here we 
have determined the intracellular distribution of activity in individual cells as well as the 
spatial distribution by MAR in tumor spheroids. By incorporating the experimentally 
determined radioactivity distribution with robust MC simulation, it is possible to construct 
models to predict radiobiological endpoints. For this reason monodisperse spherical RCP 
cells reflecting the variation in cell/nuclei radii and radioactivity distribution were used to 
generate monolayer and 3-D MC spheroid models. 
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When comparing MC(1) calculated SFcal after 1 h incubation with 111In-EGF to experimental 
results (Table 2), we note differences of up to 33% for MDA-MB-468. In contrast, Cai et al 
(14) reported differences of less than 4% between MC calculated and experimental results. 
The main contributing factors for these discrepancies can be ascribed to the bigger cell radii 
reported in this paper and activity estimation, which was determined by trapezoidal 
integration in this instance and not assuming instantaneous uptake. When taking these two 
factors into consideration, SFcal does not adequately predict SFexp.  
One aspect that we have not addressed is the adoption of radiosensitivity parameters for the 
different cell lines generated by 137Cs irradiation. With a protracted radiation delivery as is 
the case with TRT, radiation repair will occur and the Lea-Catcheside factor can no longer be 
assumed to be 1 (Supplemental Table 2). Furthermore, the α-component from high dose rate 
137Cs-irradiation is likely to overestimate the radiosensitivity compared to internalized 111In 
apart from the scenario where 111In is incorporated or close to the DNA in the nucleus. It has 
been noted that there is a difference in radiotoxicity arising from self- and cross-irradiation, 
especially with AE-emitting radionuclides associated with the DNA (30). To account for this, 
MC(2) incorporated RBE-adjusted α/β ratios for nucleus associated AE-emitters, with 
subsequent good correlation with experimental SFs. A further iteration, MC(3), which took 
repair into consideration, resulted in an
 
even better prediction of SFexp. However, TCP 
probability estimates (Fig. 7) clearly show that only those cells with a high enough nuclear 
activity uptake will accumulate a lethal dose, while neighboring cells are spared (15,31). 
Considering that spheroids are representative of micrometastases in their pre-vascular stage 
of development, the results observed here confirm that the single most important aspect that 
will determine the biological efficacy of an AE-emitting targeting strategy is the uniform 
nuclear accumulation of the construct. Even though 111In-Tz was uniformly distributed 
throughout the 231-H2N spheroid, TCP was not achieved as a result of limited nuclear 
accumulation. Similarly, while EGFR expression level is similar in SQ20B and MDA-MB-
468 cells, the nuclear accumulation of 111In-EGF was much less for SQ20B than MDA-MB-
468. Also the 3-D morphology of the spheroid prohibited adequate penetration of 111In-EGF 
resulting in a negligible TCP. Given these results, it is plausible that an AE-emitting TRT 
agent could be used in a clinical scenario to target limited volume disseminated cancer and 
micrometastases. Indeed, in the first-in-human trial using 111In-EGF tumor localization was 
achieved without any serious adverse effects (32). 
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CONCLUSION  
It is essential when evaluating the distribution of radionuclides in models of micrometastatic 
disease to include biological endpoints such as TCP. As shown here, the spatial distribution 
of radioactivity at sub-cellular and multi-cellular levels are a clear indicator of biological 
effect and TCP. 
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FIGURE LEGENDS 
FIGURE 1. (A) Packing of monodisperse spherical RCP cells according to the cell size 
distribution of the MDA-MB-468 cell line. (B) Cross-section through a spheroid showing the 
variation of cell and nucleus radii according to their Gaussian distribution. (C) Distribution of 
sampled cell and nucleus radii of the MDA-MB-468 cell line. 
FIGURE 2. Light microscopy images showing 3-D spheroids of (A) MDA-MB-468, (B) 
SQ20B and (C) 231-H2N produced using the hanging droplet method (scale bar: 100 µm). 
Confocal microscopy images of associated cell sizes, membrane (green - wheat germ 
agglutinin) and nuclei (blue - DAPI) for (D) MDA-MB-468, (E) SQ20B and (F) 231-H2N 
(scale bar: 20 µm). 
FIGURE 3. Spatial distribution of 111In-EGF in MDA-MB-468 spheroids. 
Microautoradiograms of 8 µm spheroid sections after (A) 1 h (insert shows control) and (B) 
24 h treatment. (C) γH2AX expression in consecutive spheroid section after 24 h treatment – 
insert shows uniform distribution of foci within cells throughout the spheroid. (D) 
Internalized activity (mBq/cell) determined at 1 and 24 h incubation. *p<0.05, ns = not 
significant. 
FIGURE 4. Spatial distribution of 111In-EGF in SQ20B spheroids.  Microautoradiograms of 
8 µm spheroid sections after (A) 1 h (insert shows control) and (B) 24 h treatment. (C) 
γH2AX expression in consecutive spheroid section after 24h treatment – insert shows 
peripheral distribution of foci within the spheroid. (D) Internalized activity (mBq/cell) 
determined at 1 and 24 h incubation. *p<0.05, ns = not significant. 
FIGURE 5. Spatial distribution of 111In-Tz in 231-H2N spheroids.  Microautoradiograms of 
8 µm spheroid sections after (A) 1 h (insert shows control) and (B) 24 h treatment. (C) 
γH2AX expression in consecutive spheroid section after 24 h treatment. (D) Internalized 
activity (mBq/cell) determined at 1 and 24 h incubation. *p<0.05, ns = not significant. 
FIGURE 6. Clonogenic survival of MDA-MB-468, SQ20B and 231-H2N cells after 1 or 24 h 
treatment with (A) 111In-EGF (8 MBq/µg, 40 nM) or (B) 111In-Tz (6 MBq/µg, 10 nM). Error 
bars: SD of mean SF, n = 3. 
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FIGURE 7. MC-simulated dose histograms of (A) MDA-MB-468 and (B) SQ20B spheroids 
after 24 h exposure to 111In-EGF and TCP for each dose bin of 0.5 Gy (right vertical axis).  
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TABLES  
TABLE 1 
Cellular S-values (Gy/Bq s) for different geometric models and cell lines. 
 Single cellsa Monolayerb Cluster – RCPb 
 
S(N←N) S(N←Cy) S(N←Cs) S(N←N) S(N←Cy) S(N←Cs) S(N←N) S(N←Cy) S(N←Cs) 
M
D
A
-
46
8 
7.08E-04 8.47E-05 4.30E-05 
9.83E-04 
±7.36E-04 
1.53E-04 
±8.85E-05 
1.04E-04 
±5.86E-05 
1.07E-03 
±1.12E-03 
1.94E-04 
±7.63E-05 
1.42E-04 
±4.92E-05 
SQ
20
B 
4.21E-04 5.63E-05 3.21E-05 
5.75E-04 
±3.63E-04 
1.01E-04 
±2.84E-05 
7.21E-05 
±2.06E-05 
7.10E-04 
±8.30E-04 
1.43E-04 
±5.95E-05 
1.09E-04 
±3.93E-05 
23
1-
H
2N
 
6.04E-04 5.35E-05 2.01E-05 
1.01E-03  
±1.33E-03 
1.19E-04 
±8.83E-05 
6.98E-05 
±5.66E-05 
1.02E-03  
±1.95E-03 
1.45E-04 
±1.04E-04 
9.49E-05 
±6.27E-05 
aS-values of each cell line are determined by MC simulation for the average cell and nucleus radii 
given in Figure 2(D-F).  
bMean S-value ± SD, for varied cell/nuclei radii (packing ratio for RCP ≈ 0.17). 
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TABLE 2 
Comparison of SF in 111In-treated tumor spheroids. 
  MDA-468 SQ20B 231-H2N 
  1 h 24 h 1 h 24 h 1 h 24 h 
11
In
-E
G
F 


 cell (Bq s)  331 19558 242 15594 13 1533 


 nucleus (Bq s) 72 3688 42 1597 2 108 
SFexpb 0.71(10)c 0.01(1) 0.95(15) 0.35(12) 0.92(9) 0.99(5) 
SFMC(1)d 0.95 0.13 0.99 0.66 1.00 0.97 
SFMIRDcelle 0.92 0.09 0.94 0.42 1.00 0.91 
SFMC(2)f 0.87 0.01 0.98 0.43 1.00 0.93 
SFMC(3)g 0.88 0.01 0.98 0.43 1.00 0.94 
11
In
-
Tz
 


  (Bq s)a 10 1026 14 1274 96 5947 


  nucleus (Bq s) 1 67 2 170 46 1884 
SFexpb 0.97(5) 0.75(4) 1.10(6) 1.08(16) 0.87(17) 0.46(9) 
SFMC(1)d 1.00 0.92 1.00 0.96 0.99 0.67 
SFMIRDcelle 1.00 0.89 1.00 0.90 0.98 0.69 
SFMC(2)f 1.00 0.84 1.00 0.91 0.97 0.19 
SFMC(3)g 1.00 0.85 1.00 0.91 0.97 0.38 
a


 is derived from the mean whole-cell internalized activity using the trapezoidal integration. 
bSFexp derived from technical triplicates. 
c0.71(10) means 0.71±0.10. 
dMC(1) is MC-derived SF based on the α and β values determined from 137Cs irradiation. 
eCalculated using the mean cell/nucleus radius. α and β values from 137Cs irradiation are adopted for 
self and cross doses. 
fMC(2) is similar to MC(1) but RBE=4 is applied to dose deposited by radiation sources in the 
nucleus (33,34). 
gMC(3) is similar to MC(2) but Lea-Catcheside factor, G is applied. G=0.89 for cells incubated for 1 
h. For cells incubated for 24 h, G for all cell lines are tabulated in Supplemental Table 2. All 
calculations assumed a repair half-time of 1.5 h. 







